O'Brien Patrick 4
4 · ARROWHEAD PHARMACEUTICALS, INC. · Filed Jan 5, 2026
Insider Transaction Report
Form 4
Transactions
- Gift
Common Stock
[F1][F2]2025-12-31−560→ 526,641 total - Gift
Common Stock
[F1][F2]2025-12-31−560→ 526,081 total - Gift
Common Stock
[F1][F2]2025-12-31−560→ 525,521 total - Gift
Common Stock
[F1][F2]2025-12-31−560→ 524,961 total - Gift
Common Stock
[F1][F2]2025-12-31−560→ 524,401 total - Sale
Common Stock
[F3][F4][F5][F2]2026-01-05$61.20/sh−4,368$267,322→ 520,033 total - Sale
Common Stock
[F3][F4][F6][F2]2026-01-05$62.23/sh−6,164$383,586→ 513,869 total - Sale
Common Stock
[F3][F4][F7][F2]2026-01-05$62.96/sh−13,451$846,875→ 500,418 total - Sale
Common Stock
[F3][F4][F8][F2]2026-01-05$63.84/sh−11,842$755,993→ 488,576 total - Sale
Common Stock
[F3][F4][F9][F2]2026-01-05$64.44/sh−2,700$173,988→ 485,876 total - Sale
Common Stock
[F3][F4][F10][F2]2026-01-05$66.01/sh−900$59,409→ 484,976 total - Sale
Common Stock
[F3][F4][F2]2026-01-05$68.00/sh−313$21,284→ 484,663 total - Sale
Common Stock
[F3][F11][F2]2026-01-05$61.12/sh−600$36,672→ 484,063 total - Sale
Common Stock
[F3][F12][F2]2026-01-05$62.25/sh−900$56,025→ 483,163 total - Sale
Common Stock
[F3][F13][F2]2026-01-05$62.91/sh−5,873$369,470→ 477,290 total - Sale
Common Stock
[F3][F14][F2]2026-01-05$64.04/sh−2,336$149,597→ 474,954 total - Sale
Common Stock
[F3][F2]2026-01-05$68.00/sh−46$3,128→ 474,908 total
Footnotes (14)
- [F1]Gift to relatives
- [F10]The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $65.85 to $66.12, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
- [F11]The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $60.75 to $61.56, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
- [F12]The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $61.84 to $62.48, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
- [F13]The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $62.54 to $63.39, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
- [F14]The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $63.58 to $64.46, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
- [F2]Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.
- [F3]Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
- [F4]Partial disposition of shares to satisfy tax withholding obligations.
- [F5]The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $60.85 to $61.64, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
- [F6]The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $61.66 to $62.54, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
- [F7]The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $62.55 to $63.38, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
- [F8]The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $63.41 to $64.35, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
- [F9]The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $64.36 to $64.70, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
Signature
/s/Patrick O'Brien|2026-01-05